Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a rheumatoid arthritis drug tame Immunotherapy's side effects?

NCT ID NCT04940299

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combination is safe enough to allow more patients to benefit from powerful immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tocilizumab (a drug that calms the immune system) combined with ipilimumab and nivolumab (immunotherapy drugs that help the immune system attack cancer)
What this could lead to
If it works, this could make a powerful but harsh cancer treatment safer and more tolerable for more patients.
What could go wrong
This is a small, early-phase study with only 35 participants, so results may not apply to everyone. Adding tocilizumab could also reduce the immune system's cancer-fighting power.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma cancer carcinoma of urethra cutaneous melanoma infiltrating bladder urothelial carcinoma lung cancer lung neoplasm malignant renal pelvis neoplasm melanoma metastatic melanoma non-small cell lung carcinoma renal pelvis carcinoma renal pelvis urothelial carcinoma stage IVb bladder cancer ureter cancer ureter transitional cell carcinoma urethra cancer urethra transitional cell carcinoma Urethral Neoplasms urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 LOCALLY ADVANCED BLADDER CARCINOMA LOCALLY ADVANCED BLADDER UROTHELIAL CARCINOMA LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA LOCALLY ADVANCED RENAL PELVIS CARCINOMA LOCALLY ADVANCED RENAL PELVIS UROTHELIAL CARCINOMA LOCALLY ADVANCED URETER UROTHELIAL CARCINOMA LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA MALIGNANT SOLID NEOPLASM METASTATIC BLADDER CARCINOMA METASTATIC BLADDER UROTHELIAL CARCINOMA METASTATIC LUNG NON-SMALL CELL CARCINOMA METASTATIC MELANOMA METASTATIC RENAL PELVIS UROTHELIAL CARCINOMA METASTATIC URETER UROTHELIAL CARCINOMA METASTATIC URETHRAL CARCINOMA METASTATIC URETHRAL UROTHELIAL CARCINOMA PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIID CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8 STAGE III BLADDER CANCER AJCC V8 STAGE III LUNG CANCER AJCC V8 STAGE III RENAL PELVIS CANCER AJCC V8 STAGE III URETER CANCER AJCC V8 STAGE III URETHRAL CANCER AJCC V8 STAGE IIIA BLADDER CANCER AJCC V8 STAGE IIIA LUNG CANCER AJCC V8 STAGE IIIB BLADDER CANCER AJCC V8 STAGE IIIB LUNG CANCER AJCC V8 STAGE IIIC LUNG CANCER AJCC V8 STAGE IV BLADDER CANCER AJCC V8 STAGE IV LUNG CANCER AJCC V6 STAGE IV RENAL PELVIS CANCER AJCC V8 STAGE IV URETER CANCER AJCC V8 STAGE IV URETHRAL CANCER AJCC V8 STAGE IVA LUNG CANCER AJCC V8 STAGE IVB LUNG CANCER AJCC V8 UNRESECTABLE MELANOMA

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.